American Antitrust Institute Successfully Opposes Drug Makers’ Attempts to Enjoin New California Law Outlawing Pay-for-Delay Drug Settlements

Drug Antitrust Litigation

Lieff Cabraser serves as counsel for amicus AAI, who successfully secured denial of drug makers’ requested injunction against the new pro-competition law AB 824

Lieff Cabraser serves as counsel for amicus American Antitrust Institute, on whose behalf the firm filed a brief in opposition to drug makers’ attempts to enjoin a new California law (AB 824) which outlaws pay-for-delay drug settlements. The motion for preliminary injunction against Assembly Bill 824 was brought by the so-called “Association for Accessible Medicine.” [Read more…]